The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.
Their lead drug Vascepa, a purified fish oil derivative, was approved by the FDA all the way back in 2012 to treat patients with severe hypertriglyceridemia (SHTG). But it’s not Vascepa’s potential in treating SHTG patients that’s got Wall Street excited. Rather, it’s a supplemental new drug application stemming from a five-year Harvard study in 8,179 people with milder (but still high) triglyceride levels. The results showed that the aggregate risk of heart attack, stroke, and death in these patients by 25%. In other words, if Vascepa were to be approved for an expanded label indication to reduce the risk of major adverse cardiovascular events, its potential pool of patients could grow tenfold, as would its sales potential.
Hoping for another pop today having got further FDA approval. Trading was halted most of yesterday I believe.
If approved by the FDA by the 28 December action date – as now seems likely – the new label could hike the number of patients eligible for treatment with Vascepa from around 600,000 to as many as 10 million, and catapult the drug into multibillion-dollar territory.
Don’t worry I won’t be selling. They’re on such a good run that I think they’ll be bought out. Bristol-Myers is one of my largest holdings, I’d love if they buy Amarin.
My aunt works in biotech VC I should really get some names off her that could soar. I’ll add them to the stocks request in the future hopefully
Interesting, I read an article about Bristol-Myers possibly buying one of their partners Exelixis for CheckMate 9ER. Not sure about the sources as I just make small notes for my watch list.
Up 5% today to bring my total gains on this stock to 53%. It would have been my Q1 pick for the league had it not had such a gain in the past month and a bit
Yeah, I re-requested Amarin on Trading212 community, this request was only few hours back and it got answered . Hope invest by Freetrade platform hits out soon and stock request gets easier and quicker.
Found out today that they funnel a lot of their profits through Ireland. Happy days 12.5% corporate tax rate
Edit: thank you to the community for putting a few votes on this. It was only really myself and zylan on this. I try to vote for every request if they’re not a us based etf
Also if you request a stock please vote for your own stock. How are FT ever gonna add it if you haven’t voted for your own request Not a dig at you @Zylan at all but I see it on other threads
In the wake of the US approval, Amarin raised its forecast for 2020 sales to somewhere between $650 million and $700 million. That compares to sales of $229 million in 2018
The Irish-headquartered business has already settled similar claims with Teva, one of the largest generics producers, in a move that is likely to block the introduction of generic competition by Teva for Vascepa till 2029. That would give the business a clear nine-year run to establish its product and maximise sales.
. Hope invest by Freetrade platform hits out soon and stock request gets easier and quicker.
Not a dig at you 